

Alessio Aghemo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7632009/alessio-aghemo-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

281
papers

9,381
citations

43
h-index

91
g-index

400
ext. papers

11,904
ext. citations

4.9
avg, IF

6.74
L-index

#	Paper	IF	Citations
281	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function.. <i>Digestive and Liver Disease</i> , 2022 ,	3.3	4
280	Safety of current antiviral drugs for chronic hepatitis B.. <i>Expert Opinion on Drug Safety</i> , 2022 , 1-7	4.1	2
279	High prevalence of porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels.. <i>Liver International</i> , 2022 ,	7.9	
278	Cost Analysis of Platelet Transfusion in Italy for Patients with Chronic Liver Disease and Associated Thrombocytopenia Undergoing Elective Procedures.. <i>ClinicoEconomics and Outcomes Research</i> , 2022 , 14, 205-220	1.7	
277	Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges.. <i>World Journal of Gastroenterology</i> , 2022 , 28, 1430-1443	5.6	
276	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 , 7, 396-415	18.8	11
275	Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.. <i>Advances in Therapy</i> , 2022 , 1	4.1	0
274	Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions. <i>Viruses</i> , 2022 , 14, 1096	6.2	2
273	Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 9342	2.6	0
272	Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 3187-3197	8.8	30
271	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021 , 41, 1227-1242	7.9	20
270	Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. <i>Digestive and Liver Disease</i> , 2021 ,	3.3	4
269	Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients. <i>Med</i> , 2021 , 2, 435-447.e4	31.7	6
268	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021 , 53, 1603-1609	3.3	
267	Critical Care Outreach Team During COVID-19: Ventilatory Support in the Ward and Outcomes. <i>Respiratory Care</i> , 2021 , 66, 928-935	2.1	0
266	A risk score based on baseline risk factors for predicting mortality in COVID-19 patients. <i>Current Medical Research and Opinion</i> , 2021 , 37, 917-927	2.5	3
265	Return to Work After Coronavirus Disease 2019 Acute Respiratory Distress Syndrome and Intensive Care Admission: Prospective, Case Series at 6 Months From Hospital Discharge. <i>Critical Care Medicine</i> , 2021 , 49, e1157-e1162	1.4	3

264	Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 839-843	4.1	1
263	The effect of COVID-19 epidemic on vital signs in hospitalized patients: a pre-post heat-map study from a large teaching hospital. <i>Journal of Clinical Monitoring and Computing</i> , 2021 , 1	2	1
262	High prevalence of multidrug-resistant bacteria in patients with pyogenic liver abscess following liver cancer loco-regional treatments. <i>Liver International</i> , 2021 , 41, 1909-1912	7.9	0
261	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021 , 53, 677-681	3.3	7
260	Short-term health-related quality of life, physical function and psychological consequences of severe COVID-19. <i>Annals of Intensive Care</i> , 2021 , 11, 91	8.9	14
259	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. <i>Gastroenterology</i> , 2021 , 160, 2435-2450.e34	13.3	45
258	Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?. <i>Viruses</i> , 2021 , 13,	6.2	2
257	What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective. <i>United European Gastroenterology Journal</i> , 2021 , 9, 787	5.3	1
256	Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 2203-2222	6.2	2
255	Virtual Biopsy for Diagnosis of Chemotherapy-Associated Liver Injuries and Steatohepatitis: A Combined Radiomic and Clinical Model in Patients with Colorectal Liver Metastases. <i>Cancers</i> , 2021 , 13,	6.6	3
254	COVID-19 and the liver: A 2021 update. <i>Liver International</i> , 2021 , 41, 1988-1998	7.9	8
253	Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. <i>Liver International</i> , 2021 , 41, 2228-2232	7.9	4
252	Impact of COVID-19 on global HCV elimination efforts. <i>Journal of Hepatology</i> , 2021 , 74, 31-36	13.4	80
251	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021 , 53, 612-619	3.3	3
250	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 12-19	3.4	12
249	The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy. <i>International Journal of Cardiology</i> , 2021 , 324, 249-254	3.2	17
248	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021 , 74, 801-810	13.4	12
247	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 558-568	3.4	0

246	Vasculitis changes in COVID-19 survivors with persistent symptoms: an [F]FDG-PET/CT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1460-1466	8.8	56
245	Should individuals who have been cured of hepatitis C virus and their partners be allowed to donate blood?. <i>Lancet Haematology</i> , 2021 , 8, e8-e10	14.6	
244	Stay (GI) Healthy: COVID-19 and Gastrointestinal Manifestations. <i>Techniques and Innovations in Gastrointestinal Endoscopy</i> , 2021 , 23, 179-189	1.3	9
243	Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements. <i>Liver International</i> , 2021 , 41, 649-655	7.9	7
242	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. <i>Liver International</i> , 2021 , 41, 1802-1814	7.9	8
241	COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. <i>British Journal of Haematology</i> , 2021 , 193, 43-51	4.5	20
240	Is there an 'ideal' diet for patients with NAFLD?. <i>European Journal of Clinical Investigation</i> , 2021 , e13659	4.6	2
239	Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. <i>Liver International</i> , 2021 ,	7.9	2
238	Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients. <i>Digestive and Liver Disease</i> , 2021 , 53, 1232-1234	3.3	1
237	Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: need for a Regional programmatic approach on screening and linkage to care. Commentary. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2021 , 57, 201-204	1.6	
236	Liver tests abnormalities in COVID-19: trick or treat?. <i>Journal of Hepatology</i> , 2020 , 73, 1275-1276	13.4	30
235	High mortality in COVID-19 patients with mild respiratory disease. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13314	4.6	21
234	Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 412-414	6.4	36
233	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020 , 383, 1522-1534	59.2	913
232	High rates of 30-day mortality in patients with cirrhosis and COVID-19. <i>Journal of Hepatology</i> , 2020 , 73, 1063-1071	13.4	158
231	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma. <i>PLoS ONE</i> , 2020 , 15, e0232371	3.7	11
230	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. <i>Journal of Autoimmunity</i> , 2020 , 114, 102511	15.5	53
229	Postsustained Virological Response Management in Hepatitis C Patients. <i>Seminars in Liver Disease</i> , 2020 , 40, 233-239	7.3	4

228	Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort. <i>Liver International</i> , 2020 , 40, 769-777	7.9	11
227	Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma. <i>Updates in Surgery</i> , 2020 , 72, 413-421	2.9	3
226	Gastroenterology department operational reorganisation at the time of covid-19 outbreak: an Italian and Chinese experience. <i>Gut</i> , 2020 , 69, 981-983	19.2	26
225	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. <i>Blood</i> , 2020 , 136, 6-8	2.2	1
224	Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	86
223	COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2366-2368.e3	6.9	35
222	Clinical Management of Nonrespiratory Diseases in the COVID-19 Pandemic: What Have We Done and What Needs to Be Done?. <i>Telemedicine Journal and E-Health</i> , 2020 , 26, 1206-1208	5.9	7
221	Gastrointestinal involvement attenuates COVID-19 severity and mortality 2020 ,		19
220	Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review. <i>Liver Cancer</i> , 2020 , 9, 15-27	9.1	33
219	Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials. <i>Liver International</i> , 2020 , 40, 778-786	7.9	13
218	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. <i>Digestive and Liver Disease</i> , 2020 , 52, 190-198	3.3	6
217	High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study. <i>Liver International</i> , 2020 , 40, 1062-1068	7.9	5
216	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , 2020 , 52, 937-941	3.3	22
215	Reply to: Correspondence on "High rates of 30-day mortality in patients with cirrhosis and COVID-19". <i>Journal of Hepatology</i> , 2020 , 73, 1570-1571	13.4	6
214	EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , 2020 , 73, 1170-1218	13.4	237
213	Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. <i>Heart</i> , 2020 , 106, 1512-1518	5.1	51
212	Management of patients with autoimmune liver disease during COVID-19 pandemic. <i>Journal of Hepatology</i> , 2020 , 73, 453-455	13.4	40
211	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma 2020 , 15, e0232371		

210	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma 2020 , 15, e0232371		
209	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma 2020 , 15, e0232371		
208	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma 2020 , 15, e0232371		
207	JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. <i>Hepatology</i> , 2019 , 69, 2349-2363	11.2	5
206	Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2019 , 51, 1135-1140	3.3	16
205	Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2019 , 23, 2216-2224	3.3	13
204	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019 , 9, 3682	4.9	42
203	The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. <i>Journal of Autoimmunity</i> , 2019 , 100, 17-26	15.5	18
202	Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. <i>Journal of Hepatology</i> , 2019 , 71, 1106-1115	13.4	36
201	Safety of vedolizumab in liver transplant recipients: A systematic review. <i>United European Gastroenterology Journal</i> , 2019 , 7, 875-880	5.3	2
200	Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 341-341	2.2	1
199	Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure. <i>Clinical and Molecular Hepatology</i> , 2019 , 25, 360-365	6.9	6
198	Role of liver biopsy in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019 , 25, 6041-6052	5.6	33
197	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. <i>Nutrients</i> , 2019 , 11,	6.7	27
196	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 117-138	5.3	5
195	Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 5-6	18.8	
194	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2019 , 51, 310-317	3.3	29
193	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2019 , 70, 379-387	13.4	87

192	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 135-184	18.8	216
191	Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1183-1191.e7	6.9	53
190	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Infection</i> , 2019 , 47, 141-168	5.8	
189	Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage. <i>Viral Immunology</i> , 2018 , 31, 358-361	1.7	1
188	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018 , 69, 461-511	13.4	1079
187	Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up. <i>International Journal of Artificial Organs</i> , 2018 , 41, 306-318	1.9	5
186	What do clinicians need to watch for with direct-acting antiviral therapy?. <i>Journal of the International AIDS Society</i> , 2018 , 21 Suppl 2, e25076	5.4	7
185	Glecaprevir/Pibrentasvir: The Final Piece in the Hepatitis C Virus Treatment Puzzle?. <i>Gastroenterology</i> , 2018 , 154, 1195-1196	13.3	0
184	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression. <i>Liver International</i> , 2018 , 38, 1459-1467	7.9	21
183	High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1705-1712 ²¹	6.1	21
182	Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study. <i>Journal of Hepatology</i> , 2018 , 68, S65	13.4	8
181	12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis. <i>Digestive and Liver Disease</i> , 2018 , 50, 703-706	3.3	
180	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 125-133	18.8	98
179	Managing Patients With Nonalcoholic Fatty Liver Disease: Is It Really Only About Fibrosis?. <i>Gastroenterology</i> , 2018 , 155, 926-928	13.3	1
178	Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3 year study. <i>Journal of Hepatology</i> , 2018 , 68, S529	13.4	3
177	Screening of esophagogastric varices: Performance of the Expanded Baveno VI criteria and the platelet 150/MELD 6 strategy in all etiology compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2018 , 68, S734-S735	13.4	2
176	Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STILy observational study. <i>Medicine (United States)</i> , 2018 , 97, e11307	1.8	2
175	Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018 , 17, 570-574	2.1	1

174	Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report. <i>Hepatology Communications</i> , 2018 , 2, 1179-1183	6	8
173	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Journal of Nephrology</i> , 2018 , 31, 1133-1144	3.7	2
172	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Journal of Nephrology</i> , 2018 , 31, 1133-1144	4.8	3
171	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Digestive and Liver Disease</i> , 2018 , 50, 1133-1152	3.3	2
170	No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals. <i>Liver International</i> , 2018 , 38, 2342-2342.	7.9	
169	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018 , 46, 607-615	5.8	7
168	SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study. <i>Journal of Hepatology</i> , 2018 , 68, S86	13.4	2
167	The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat. <i>Journal of Hepatology</i> , 2018 , 69, 1188-1196	13.4	62
166	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 52-62	18.8	43
165	Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. <i>Liver International</i> , 2017 , 37, 1295-1303	7.9	14
164	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017 , 49, 731-741	3.3	14
163	Treatment of chronic hepatitis C: can complexity pave the way towards elimination?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 465-466	18.8	
162	Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. <i>Liver International</i> , 2017 , 37, 1526-1534	7.9	29
161	Direct-acting antivirals: the endgame for hepatitis C?. <i>Current Opinion in Virology</i> , 2017 , 24, 31-37	7.5	62
160	Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe. <i>Journal of Hepatology</i> , 2017 , 66, S95-S96	13.4	12
159	Screening of oesophagogastric varices in virus-related compensated advanced chronic liver disease: Beyond the Baveno VI criteria. <i>Digestive and Liver Disease</i> , 2017 , 49, e38	3.3	5
158	Genotype 3 infection in DAA era: Reports of a real life Northern Italy Network for viral hepatitis after 2 years by the start. <i>Digestive and Liver Disease</i> , 2017 , 49, e68	3.3	2
157	Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?. <i>Liver International</i> , 2017 , 37, 950-962	9.6	36

156	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
155	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017 , 7, 4492	4.9	131
154	Treatment of Extrahepatic Manifestations of Hepatitis C Virus. <i>Clinics in Liver Disease</i> , 2017 , 21, 631-643	4.6	16
153	Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2017 , 166, 109-117	8	138
152	Analisi Economica Associata all'utilizzo Di Due Test (Real-Time PCR-Based) per Valutare La Determinazione Dell'HCV-RNA Nei Pazienti HCV Genotipo 1 in Trattamento Con Duplice o Triplice Terapia. <i>Global & Regional Health Technology Assessment</i> , 2017 , 4, grhta.5000248	0.2	
151	Liver stiffness measurement reliability and main determinants of point shear-wave elastography in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 356-65	6.1	27
150	Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature. <i>Liver International</i> , 2016 , 36, 1585-1589	7.9	21
149	Ledipasvir/Sofosbuvir for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 Hcv Infection. <i>Journal of Hepatology</i> , 2016 , 64, S183	13.4	11
148	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016 , 48, 995-1005	3.3	12
147	Reply. <i>Hepatology</i> , 2016 , 63, 1052-3	11.2	
146	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 739-50	5.1	12
145	Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. <i>Gut</i> , 2016 , 65, 1998-2006	19.2	35
144	No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered?. <i>Gastroenterology</i> , 2016 , 150, 1241-1243	13.3	1
143	Screening and surveillance of esophageal varices: Validation of Baveno VI criteria in a cohort of cirrhotic HCV patients. <i>Digestive and Liver Disease</i> , 2016 , 48, e17	3.3	3
142	Deciding on Interferon-Free Treatment for Chronic Hepatitis C: Updating Liver Stiffness Cut-Off Values to Maximize Benefit. <i>PLoS ONE</i> , 2016 , 11, e0164452	3.7	6
141	Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. <i>PLoS ONE</i> , 2016 , 11, e0155967	3.7	19
140	DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. <i>Hepatology</i> , 2016 , 63, 418-27	11.2	29
139	Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1331-6	6.9	29

138	Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. <i>Journal of Hepatology</i> , 2016 , 64, 1217-23	13.4	84
137	Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 1373-1383	4.2	10
136	Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network. <i>European Review for Medical and Pharmacological Sciences</i> , 2016 , 20, 17-19	2.9	1
135	Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era?. <i>Gastroenterology</i> , 2015 , 149, 500-1	13.3	
134	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. <i>Hepatology</i> , 2015 , 62, 111-7	11.2	46
133	Genotype 2 Patients: What is the Optimum Therapy so Far?. <i>Current Hepatology Reports</i> , 2015 , 14, 253-259		
132	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. <i>Gut</i> , 2015 , 64, 1824-33	19.2	99
131	Recommendations for the management of hepatitis C virus infection among people who inject drugs. <i>International Journal of Drug Policy</i> , 2015 , 26, 1028-38	5.5	132
130	Contribution of β cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. <i>Journal of Hepatology</i> , 2015 , 63, 1484-90	13.4	38
129	Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". <i>Journal of Hepatology</i> , 2015 , 63, 1535-6	13.4	3
128	Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals?. <i>Journal of Hepatology</i> , 2015 , 63, 1294	13.4	4
127	Daclatasvir for the treatment of chronic hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2679-88	19.2	6
126	Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?. <i>Liver International</i> , 2015 , 35, 1-4	7.9	21
125	Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. <i>Gut</i> , 2015 , 64, 860-2	19.2	5
124	Estimating HCV disease burden - volume 3 (editorial). <i>Journal of Viral Hepatitis</i> , 2015 , 22 Suppl 4, 1-3	3.4	11
123	Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. <i>Liver Transplantation</i> , 2015 , 21, 1259-69	4.5	31
122	Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. <i>International Journal of Drug Policy</i> , 2015 , 101669-101669	5.5	
121	Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 473-84	4.1	8

120	Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity. <i>PLoS ONE</i> , 2015 , 10, e0138546	3.7	7
119	De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review). <i>Digestive Diseases and Sciences</i> , 2014 , 59, 691-5	4	5
118	Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 90-8	3.4	43
117	Hepatitis C Virus 2014 , 859-877		
116	High-resolution melting assay for genotyping of IFNL4-associated dinucleotide variant rs368234815. <i>Clinical Microbiology and Infection</i> , 2014 , 20, O936-8	9.5	2
115	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014 , 46, 818-25	3.3	8
114	Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 416-23	3.4	10
113	Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 T allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients. <i>Journal of Clinical Virology</i> , 2014 , 59, 274-5	14.5	10
112	EASL recommendations on treatment of hepatitis C 2014. <i>Journal of Hepatology</i> , 2014 , 61, 373-95	13.4	161
111	Hepatitis C genotype 3: a tough match for interferon-free regimens. <i>Gastroenterology</i> , 2014 , 146, 1125-7	13.3	2
110	P1032 LOW ACCURACY OF NON-INVASIVE TESTS FOR ASSESSING RESIDUAL CIRRHOSIS IN HEPATITIS C PATIENTS WITH A SUSTAINED VIROLOGICAL RESPONSE. <i>Journal of Hepatology</i> , 2014 , 60, S418-S419	13.4	5
109	Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). <i>Digestive and Liver Disease</i> , 2014 , 46, 18-24	3.3	9
108	Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. <i>Journal of Hepatology</i> , 2014 , 60, 913-9	13.4	33
107	Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. <i>Digestive and Liver Disease</i> , 2014 , 46, 152-6	3.3	26
106	Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients. <i>Antiviral Therapy</i> , 2014 , 19, 747-53	1.6	6
105	Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir. <i>PLoS ONE</i> , 2014 , 9, e95881	3.7	13
104	Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. <i>Hepatic Medicine: Evidence and Research</i> , 2014 , 6, 25-33	3.4	18
103	Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 1067-76	7	6

102	Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study. <i>International Journal of Artificial Organs</i> , 2014 , 37, 803-8	1.9	1
101	Treatment of patients with dual hepatitis B and C: a step in the right direction. <i>Gut</i> , 2014 , 63, 380-1	19.2	9
100	Optimal Management of Hepatitis C Genotype 2 Chronic Infection. <i>Current Hepatology Reports</i> , 2014 , 13, 273-278	1	
99	The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 7213-24	6.3	17
98	Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 944-9	3.4	22
97	Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis. <i>Antiviral Therapy</i> , 2014 , 19, 527-31	1.6	17
96	Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C. <i>PLoS ONE</i> , 2014 , 9, e106022	3.7	9
95	Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms. <i>Journal of Virological Methods</i> , 2013 , 187, 271-3	2.6	3
94	Hepatitis C treatment in patients with kidney disease. <i>Kidney International</i> , 2013 , 84, 874-9	9.9	36
93	Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 553-4	6.1	1
92	Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. <i>Seminars in Immunopathology</i> , 2013 , 35, 111-20	12	25
91	Is there need for more than one IL28B single nucleotide polymorphism in hepatitis C clinical practice?. <i>Hepatology</i> , 2013 , 57, 416	11.2	2
90	Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus. <i>Gastroenterology</i> , 2013 , 145, 247-249	13.3	5
89	506 UNDETECTABLE HCV-RNA IN TELAPREVIR-TREATED PATIENTS: LOW CONCORDANCE BETWEEN TWO HIGHLY SENSITIVE REAL-TIME PCR ASSAYS. <i>Journal of Hepatology</i> , 2013 , 58, S208	13.4	2
88	Treatment of chronic hepatitis C with pegylated interferon- α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura. <i>Transfusion Medicine</i> , 2013 , 23, 66-68	1.3	2
87	How to optimize HCV therapy in genotype 2 patients. <i>Liver International</i> , 2013 , 33 Suppl 1, 35-40	7.9	11
86	The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. <i>Journal of Hepatology</i> , 2013 , 59, 251-6	13.4	106
85	New horizons in hepatitis C antiviral therapy with direct-acting antivirals. <i>Hepatology</i> , 2013 , 58, 428-38	11.2	118

84	PegIFN- α for the treatment of chronic hepatitis B and C: a 10-year history. <i>Expert Review of Anti-Infective Therapy</i> , 2013 , 11, 459-74	5.5	13
83	Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. <i>Journal of Hepatology</i> , 2013 , 59, 38-44	13.4	47
82	Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. <i>Digestive and Liver Disease</i> , 2013 , 45, 1-7	3.3	23
81	Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. <i>Digestive and Liver Disease</i> , 2013 , 45, 43-9	3.3	19
80	Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients. <i>BioMed Research International</i> , 2013 , 2013, 580796	3	3
79	Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review. <i>Kidney and Blood Pressure Research</i> , 2013 , 38, 52-60	3.1	7
78	Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis. <i>Journal of Interferon and Cytokine Research</i> , 2013 , 33, 9-14	3.5	2
77	Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 858-66	3.4	27
76	Hepatorenal syndrome and novel advances in its management. <i>Kidney and Blood Pressure Research</i> , 2013 , 37, 588-601	3.1	17
75	Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders. <i>Hepatology</i> , 2013 , 57, 2087	11.2	3
74	Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies. <i>World Journal of Gastroenterology</i> , 2013 , 19, 1359-71	5.6	17
73	Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1434-42	6.1	32
72	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. <i>Hepatology</i> , 2012 , 55, 336-42	11.2	67
71	934 DIFFERENCES IN HCV GENOTYPE 1 RVR RATES AMONG CLINICAL TRIALS IN EUROPE DEPEND ON HCV RNA ASSAY SENSITIVITY. <i>Journal of Hepatology</i> , 2012 , 56, S364	13.4	2
70	Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. <i>Hepatology</i> , 2012 , 56, 1681-7	11.2	75
69	Reply to: "The pegylated story continues [Perhaps because both ends (α a and α b) are true?]" <i>Journal of Hepatology</i> , 2012 , 57, 229	13.4	
68	Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 193-207	5.4	73
67	Hyporesponsiveness to PegIFN- α B plus ribavirin in patients with hepatitis C-related advanced fibrosis. <i>Journal of Hepatology</i> , 2012 , 56, 341-7	13.4	18

66	Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: the plot thickens. <i>Journal of Hepatology</i> , 2012 , 56, 276-8	13.4	4
65	Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. <i>Journal of Hepatology</i> , 2012 , 56, 1209-1210	13.4	17
64	Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients. <i>Journal of Hepatology</i> , 2012 , 56, 1422	13.4	2
63	Interferon-free oral therapy for hepatitis C: "faraway, so close!". <i>Gastroenterology</i> , 2012 , 142, 1253-4	13.3	1
62	Insulin resistance and response to telaprevir plus pegylated interferon and ribavirin: a requiem for the HOMA score?. <i>Gastroenterology</i> , 2012 , 143, 1685-7	13.3	
61	Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin?. <i>Medical Hypotheses</i> , 2012 , 79, 471-3	3.8	6
60	Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. <i>Journal of Hepatology</i> , 2012 , 57, 1326-35	13.4	22
59	A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. <i>Hepatology</i> , 2012 , 56, 532-43	11.2	279
58	Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. <i>Internal and Emergency Medicine</i> , 2012 , 7, 139-44	3.7	73
57	Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012 , 19 Suppl 1, 3-6	3.4	7
56	Comparative trials of peginterferon αa and peginterferon αb for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012 , 19 Suppl 1, 37-41	3.4	7
55	Treatment of patients with HCV related cirrhosis: many rewards with very few risks. <i>Hepatitis Monthly</i> , 2012 , 12, 361-8	1.8	7
54	Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. <i>Hepatitis Monthly</i> , 2012 , 12, 411-4	1.8	10
53	Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. <i>Biologics: Targets and Therapy</i> , 2012 , 6, 363-70	4.4	1
52	1318 FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C IS NOT INFLUENCED BY IL28B POLYMORPHISMS. <i>Journal of Hepatology</i> , 2011 , 54, S519	13.4	3
51	T-29 Early NK cell activation predicts successful treatment outcome in chronic HCV infection. <i>Digestive and Liver Disease</i> , 2011 , 43, S86	3.3	2
50	A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations?. <i>Gastroenterology</i> , 2011 , 140, 1347-9	13.3	1
49	A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. <i>Gastroenterology</i> , 2011 , 141, 396-9	13.3	2

48	Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011 , 35, 455-64	2.4	3
47	EASL Clinical Practice Guidelines: management of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2011 , 55, 245-64	13.4	983
46	The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. <i>Antiviral Therapy</i> , 2011 , 16, 677-84	1.6	34
45	Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. <i>Hepatology</i> , 2011 , 53, 791-9	11.2	199
44	Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. <i>Hepatology</i> , 2011 , 54, 1127-34	11.2	105
43	Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 301-13	5.4	13
42	Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. <i>Hepatitis Monthly</i> , 2011 , 11, 918-24	1.8	10
41	Predictors of Sustained Virological Response After Antiviral Therapy for Chronic Hepatitis C In Patients with Hemophilia: The Role of the Interleukin-28B (IL28B) Polymorphism. <i>Blood</i> , 2011 , 118, 2276-2276	2.2	2
40	Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. <i>Hepatitis Monthly</i> , 2011 , 11, 918-924	1.8	6
39	Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. <i>Gastroenterology</i> , 2010 , 138, 108-15	13.3	173
38	Peginterferon Alfa-2B versus peginterferon Alfa-2A with ribavirin for the treatment of chronic hepatitis C: the pursuit of an ideal. <i>Gastroenterology</i> , 2010 , 138, 386-9; discussion 389-90	13.3	6
37	Genetic variation in interleukin-28B predicts hepatitis C treatment-induced viral clearance in genotype 1 patients: the dawn of a new era?. <i>Gastroenterology</i> , 2010 , 138, 2546-9	13.3	2
36	Telaprevir for hepatitis C re-treatment: an open door on a long and winding road. <i>Gastroenterology</i> , 2010 , 139, 1412-6; discussion 1416	13.3	2
35	291 INSULIN RESISTANCE DOES NOT PREDICT A RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A SUB-ANALYSIS OF THE MIST STUDY. <i>Journal of Hepatology</i> , 2010 , 52, S122	13.4	2
34	Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010 , 7, 485-94	24.2	54
33	A review of the treatment of chronic hepatitis C virus infection in cirrhosis. <i>Clinical Therapeutics</i> , 2010 , 32, 2117-38	3.5	80
32	Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. <i>Hepatology</i> , 2010 , 52, 249-55	11.2	103
31	Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy. <i>Hepatology</i> , 2010 , 52, 1170-1	11.2	6

30	Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. <i>Hepatology</i> , 2010 , 52, 1723-30	11.2	51
29	Indolent B-Cell Lymphomas Treated Upfront with Antiviral Therapy: a Series of 13 Patients. <i>Blood</i> , 2010 , 116, 2876-2876	2.2	
28	HBV and HCV therapy. <i>Viruses</i> , 2009 , 1, 484-509	6.2	6
27	The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?. <i>Hepatology</i> , 2009 , 49, 702-3; author reply 703-4	11.2	2
26	Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 1997-2005	15.4	7
25	High levels of factor VIII and risk of extra-hepatic portal vein obstruction. <i>Journal of Hepatology</i> , 2009 , 50, 916-22	13.4	62
24	Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. <i>Journal of Hepatology</i> , 2009 , 51, 288-95	13.4	25
23	HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. <i>Journal of Hepatology</i> , 2009 , 51, 964-6	13.4	17
22	Cirrhosis regression in chronic hepatitis C: an old tale with a new ending. <i>Gastroenterology</i> , 2009 , 136, 1447-9	13.3	7
21	Treatment of nonresponder patients with chronic hepatitis C: to repeat or not to repeat? That is the question. <i>Gastroenterology</i> , 2009 , 137, 1521-4; discussion 1524	13.3	
20	Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , 2009 , 7, 925-35	5.5	18
19	794 PROSPECTIVE STUDY OF DYSPLASTIC NODULES IN CIRRHOSIS: CORRELATION WITH CT VASCULAR PATTERN, HISTOLOGY AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2009 , 50, S290-S291	13.4	2
18	The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. <i>Antiviral Therapy</i> , 2009 , 14, 789-96	1.6	13
17	The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. <i>Antiviral Therapy</i> , 2009 , 14, 577-84	1.6	16
16	The pattern of pegylated interferon-2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. <i>Antiviral Therapy</i> , 2009 , 14, 577-584	1.6	28
15	Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 471	3.4	
14	Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. <i>European Journal of Internal Medicine</i> , 2008 , 19, 370-1	3.9	23
13	Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1966-72	0.7	15

12	Anemia during Pegylated Interferon-Ribavirin Therapy Results from Both Increase Suppression of Erythroid Differentiation and Hemolysis. <i>Blood</i> , 2008 , 112, 4577-4577	2.2	
11	In Vitro Effect of Ribavirin and Pegylated Interferon on Erythropoiesis. <i>Blood</i> , 2008 , 112, 4786-4786	2.2	
10	The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis. <i>Gastroenterology</i> , 2007 , 133, 2076	13.3	
9	Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 875-82	3.4	9
8	Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. <i>Antiviral Therapy</i> , 2007 , 12, 1033-40	1.6	2
7	Lack of Rapid Virological Response Predicts Interferon- α 2b/Ribavirin Therapy failure in HCV Genotype 2 Patients: A Single-Centre Study. <i>Antiviral Therapy</i> , 2007 , 12, 1033-1040	1.6	7
6	The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. <i>Journal of Hepatology</i> , 2006 , 44, 825; author reply 825-6	13.4	1
5	Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. <i>Antiviral Therapy</i> , 2006 , 11, 797-802	1.6	6
4	Impaired Response to Interferon- α 2b plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection. <i>Antiviral Therapy</i> , 2006 , 11, 797-802	1.6	14
3	US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C. <i>Radiology</i> , 2005 , 234, 641; author reply 641	20.5	16
2	The Prevalence, Clinical Features and Response to Antiviral Therapy of Patients with Chronic Hepatitis C who are Seropositive for Liver/Kidney Microsome Type 1 Antibodies. <i>Antiviral Therapy</i> , 2005 , 10, 715-720	1.6	5
1	New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations		2